CALGARY, ALBERTA - July 9, 2026 (NEWMEDIAWIRE) - Ocumetics Technology Corp. ("Ocumetics" or the "Company") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a developer of advanced vision restoration technologies, is pleased to provide shareholders with a corporate and operational update highlighting continued progress across its clinical development program, manufacturing activities, regulatory initiatives, financing strategy and commercialization efforts.
Key Highlights
- Positive six-month results from the Company's First-in-Human ("FIH") study support advancement to Group Two clinical surgeries.
- Financing initiative launched to fund completion of the FIH study and accelerate commercialization activities.
- Next-generation accommodating intraocular lens ("Ocumetics Lens") with a breakthrough technology design completed, incorporates expected significant advancements in manufacturability, surgical performance and scalability.
- Manufacturing of the redesigned Ocumetics Lens has commenced in Germany in preparation for planned Group Two surgeries.
- Group Two surgeries remain on track for Q3 2026 in Mexico City.
- All regulatory requirements necessary to proceed to Group Two surgeries have been successfully completed.
- Strategic discussions continue with four of the world's seven largest ophthalmic companies regarding future partnership and commercialization opportunities.
Since reporting encouraging initial FIH clinical results, the Company has continued to execute on multiple strategic initiatives designed to advance the Ocumetics Lens toward commercialization. Positive six-month clinical data have supported progression to Group Two surgeries. Manufacturing of the redesigned Ocumetics Lens has commenced, regulatory milestones have been achieved, and strategic engagement with leading global ophthalmic companies continue to build momentum.
"The past several months have marked one of the most productive periods in Ocumetics' history," commented Dean Burns, President and Chief Executive Officer. " With group two surgeries expected to commence during the third quarter of 2026, we believe the Company is entering an important value-creation phase as we continue to build long-term shareholder value."
Corporate Update
Financing Initiative to Advance Clinical Development
To support completion of its FIH clinical study and prepare for subsequent regulatory submissions, the Company has launched a financing initiative intended to fund the next phase of clinical development while supporting manufacturing, regulatory and commercialization activities (see news release dated July 7, 2026).